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Establishment, optimisation and 
quantitation of a bioluminescent 
murine infection model of visceral 
leishmaniasis for systematic 
vaccine screening
Han Boon Ongの, Simon Clareは, Adam Jonathan Robertsの, Mary Elizabeth Wilsonば & 
Gavin James Wrightのこ
Visceral leishmaniasis is an infectious parasitic disease caused by the protozoan parasites Leishmania 
donovani and Leishmania infantum┻ The drugs currently used to treat visceral leishmaniasis suプer from 
toxicity and the emergence of parasite resistance, and so a better solution would be the development 
of an eプective subunit vaccine┹ however┸ no approved vaccine currently exists┻ The comparative testing 
of a large number of vaccine candidates requires a quantitative and reproducible experimental murine 
infection model┸ but the parameters that in━uence infection pathology have not been systematically 
determined. To address this, we have established an infection model using a transgenic luciferase-
expressing L. donovani parasite and longitudinally quantiボed the infections using in vivo bioluminescent 
imaging within individual mice┻ We examined the eプects of varying the infection route┸ the site of 
adjuvant formulation administration, and standardised the parasite preparation and dose. We observed 
that the increase in parasite load within the liver during the ボrst few weeks of infection was directly 
proportional to the parasite number in the initial inoculum. Finally, we show that immunity can be 
induced in pre-exposed animals that have resolved an initial infection. This murine infection model 
provides a platform for systematic subunit vaccine testing against visceral leishmaniasis.
Protozoa of the genus Leishmania are obligate intracellular parasites which cause the disease leishmaniasis. he 
parasite is transmitted by the bite of an infected female phlebotomine sand ly during a blood meal, and every 
year there are an estimated ~1 million new infections resulting in ~65,000 deaths1. Although the disease burden 
disproportionately afects poor people living in tropical and developing countries, the expanding geographic 
range of vector distribution caused by climate and environmental changes is an emerging threat outside these 
regions2–4. Outbreaks and re-emergence of leishmaniasis are also linked to other factors including political and 
socioeconomic upheavals5–7. Within the human host, Leishmania spp. cause a spectrum of species-speciic clini-
cal manifestations known as cutaneous, mucocutaneous or visceral leishmaniases, and it is the visceral form that 
is considered to be the most severe, and is ultimately fatal if let untreated. Symptomatic visceral leishmaniasis 
(VL), results from infections of L. donovani and L. infantum, and while representing only ~10% of all sympto-
matic leishmanial infections, they are responsible for nearly all leishmaniasis-attributed fatalities1. he current 
front-line drug treatments for VL: liposomal amphotericin B, miltefosine, paromomycin and antimonials, are far 
from ideal, with major concerns surrounding general toxicity or increased treatment failure8,9. While improved 
drugs are being developed10,11, the deployment of an efective vaccine would be an important disease control tool, 
but to date, no efective vaccine has been licensed for human leishmaniasis.
he earliest evidence of leishmaniasis being prevented by vaccination was the practice of leishmanisation 
where resistance to infections was induced by inoculating individuals with live parasites collected from the lesions 
of a cutaneous infection12–15. Patients who have recovered from self-healing primary infections or successful drug 
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treatments oten develop life-long immunity against re-infection15,16. he use of live organisms for vaccination, 
however, has signiicant safety concerns; consequently, modern vaccines are typically subunit vaccines: chem-
ically deined products such as recombinant proteins that can elicit protective immune responses. Developing 
these subunit vaccines usually requires a suitable experimental model to systematically test candidates. While 
the disease progression of leishmania infections in dogs and hamsters is considered to more closely relect the 
pathology of human VL infections than mice17–19, these animal models are diicult to use at the necessary scale 
because of ethical objections, lack of reagents and the diiculties with high costs of animal husbandry. To address 
these challenges, murine models for VL have been used, with infections using the susceptible BALB/c strain 
arguably being the best characterised19–21. Parasites primarily infect and multiply within liver macrophages of 
BALB/c mice during the irst few weeks of infection, before an efective immune response is raised to clear the 
liver of parasites22–24. his is followed by a delayed but progressive increase in parasite burden within the spleen 
accompanied by splenomegaly; unlike the liver, however, spleen infections are persistent and indeinitely main-
tained. Genetically modiied immuno-compromised mice such as Rag1 and Rag2-deicient mice have also been 
used successfully as models for VL and unlike the BALB/c strain, these mice more closely relect human disease 
pathology since they do not clear parasites from the liver25–28. Uses of these immunodeicient animals, however, 
are generally limited to studies involving drug trials or in vivo parasite propagation since they are incapable of 
generating adaptive immune responses.
Because of their genetic tractability and characterization, mice have become a useful model organism to char-
acterise host factors and immune responses to Leishmania spp. infections. Despite these advantages, variations in 
infection pathology within a cohort of infected animals and the diiculty of repeatedly quantifying parasite loads 
in visceral organs within an individual animal are challenges to address for comparative vaccinology studies. 
Currently, the most commonly used techniques for parasite quantiication are organ impression smears, limiting 
dilution29, and qPCR30 methods, but these methods require euthanizing the animal to access target organs lim-
iting the amount of data that can be collected per individual. hese experimental diiculties have been largely 
addressed by the use of in vivo bioluminescent imaging, where parasite burden and location can be longitudinally 
determined within individual mice by infecting animals with transgenic parasites that constitutively express a 
luciferase enzyme that generates light in the presence of the luciferin substrate. While several studies have used 
bioluminescent Leishmania spp. parasites, expressing diferent types of luciferase for a variety of purposes31–35, 
only a few have fully characterised the VL-infection progression in vivo36–38. Careful assessment and understand-
ing of how diferent parameters such as parasite dose, route of administration or how the efects of adjuvant on 
vaccine formulation may afect experimental infections is important for these models to be useful for both drug 
and especially vaccine development.
Here, we establish a reproducible and highly quantitative murine infection model for evaluating vaccine can-
didates for VL by selecting a transgenic L. donovani parasite expressing the irely luciferase and investigating 
the efects of experimental parameters that are known to inluence the progression of infection, and which could 
afect comparative vaccine testing.
Results
The inoculation route of L. donovani infection in━uences disease pathology┻ To establish a repro-
ducible and quantitative murine infection model of VL, we transfected the LV9 strain of L. donovani and selected 
a recombinant parasite that constitutively expressed the irely luciferase gene to permit tracking and quantiica-
tion of infected mice using in vivo imaging. As inoculation routes and doses are known to inluence L. infantum 
infections of mice39–42, we irst challenged groups of BALB/c mice with stationary phase promastigotes through 
intravenous, subcutaneous or intraperitoneal parasite delivery, and compared the resulting infections in each ani-
mal every week for ten weeks (Fig. 1A). Hepatic and splenic parasite loads were separately quantiied by deining 
the regions on each animal corresponding to the liver and spleen (Fig. 1B), and the rate at which the luciferin sub-
strate was oxidised to determine the optimum time for data acquisition ater luciferin administration (Fig. 1C). By 
quantifying liver bioluminescence, total light lux increased steadily during the irst 10 minutes, peaking between 
10 to 20 minutes before a gradual decline. Intravenous delivery of parasites resulted in the parasitisation of the 
liver during the irst few weeks of infection that resolved followed by dissemination and persistence within the 
spleen ater the sixth week. We observed that a higher parasite dose resulted in the parasitisation of the spleen by 
week ive, which was less evident in mice given a lower dose (Fig. 1A). To conirm that mice with bioluminescent 
signals were infected, we prepared impression smears from infected mouse spleens and were able to observe par-
asites within host cells. We noticed that it was diicult to ind infected cells on the impression smears even from 
mice with high bioluminescence signals suggesting that bioluminescence was a much more sensitive method to 
quantify parasite loads (Fig. S1).
Immunocompromised Rag1 and Rag2-deicient mice have been useful models to isolate and study compo-
nents of host immunity to VL, as well as a source of ex vivo amastigotes25–28. To determine the virulence of trans-
genic L. donovani in immunodeicient Rag1 knockout mice, they were infected intravenously with 108 stationary 
phase promastigotes and the infection followed by in vivo imaging (Fig. S2A). By contrast to immunocompe-
tent mice, Rag1-deicient mice were unable to resolve their liver infections resulting in a progressive increase in 
hepatic bioluminescence over the course of 14 weeks (Fig. S2B). Rag1-deicient mice lack mature lymphocytes 
and possess only a rudimentary spleen and so it is perhaps unsurprising that we observed little or no evidence of 
parasite-dissemination or persistence in the spleen. Indeed, splenomegaly was not observed in the post-mortem 
of these animals, suggesting parasite persistence requires adaptive an immune response.
To determine whether the route of parasite administration can afect the disease pathology in animals, par-
asites were injected either subcutaneously or into the peritoneal cavity. Mice infected subcutaneously showed 
little or no disease progression with observable parasites persisting at the site of inoculation before parasite loads 
fell below the IVIS detection limits ater ive weeks. Where parasites were inoculated into the peritoneal cavity at 
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the lower dose, parasites remained within the cavity for several weeks with no obvious progression to the liver or 
spleen. At the high dose, parasites were detected in the liver and spleen (Fig. 1A); however, signals from parasites 
that persisted in the peritoneal cavity made localising and quantifying the parasite load in the liver and spleen 
Figure 1. he route of parasite administration in experimental infections of L. donovani inluenced disease 
pathology. (A) Groups of ive mice were infected with either day ive (intraperitoneal and intravenous delivery) 
or day seven (subcutaneous) stationary-phase transgenic luciferase-expressing L. donovani promastigote 
cultures at the indicated doses. Parasite loads were quantiied at the indicated times by administering the 
luciferase substrate, luciferin, and the animals imaged using an IVIS instrument. hree representative animals 
from the group are shown and are arranged so that the infection dynamics can be followed in each individual 
animal throughout the course of the infection. he route of parasite administration and dose inluenced the 
progression of the infection. (B) Parasite loads were separately quantiied in the liver or spleen by deining these 
organs as shown and measuring the associated bioluminescence. (C) Liver bioluminescence increased over time 
following luciferin injection, peaked at between 10 to 20 minutes before a steady decrease in signal over the next 
hour. Data points represent means ± S.E.M. (n = 5, from individual mice).
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di cult. We therefore concluded that intravenous delivery of L. donovani parasites resulted in the most reproduc-
ible infections that relected what is known the disease pathology and progression in humans.
Infections are dependent on the duration of parasite culture in stationary phase. he viru-
lence of cultured L. donovani promastigotes in animals has previously been shown to be dependent on metacy-
clogenesis, a state that can be modelled during growth to stationary-phase43. To determine the optimal stationary 
phase time-point for infections, a growth analysis was performed on L. donovani promastigotes cultured in LdPro 
medium (Fig. 2A). Using an initial seeding density of 1 × 106 cells/mL, parasites continued to grow exponentially 
for three days before the stationary phase was reached at approximately 8 × 107 cells/mL. Stationary phase density 
was maintained for a further two days before the number of living cells, as determined by those that remained 
motile, declined steadily over the next seven days. To investigate the relationship between stationary-phase pro-
gression and parasite virulence, cells were harvested at regular time intervals (days 5, 7, 9 and 12) and used to 
infect BALB/c mice (Fig. 2B). Liver bioluminescence analyses of infected animals revealed that parasites har-
vested on days 7 and 9 of the culture were marginally more virulent compared to those harvested on days 5 and 
12. Based upon these observations, parasites taken from stationary phase cultures between days 7 and 9 were 
considered optimal for infections, with day 7 cultures being used for all subsequent infection studies.
The number of parasites in the inoculum aプects disease progression and severity┻ Given that 
our initial experiments had suggested the number of parasites in the initial inoculum afected subsequent disease 
progression, we extended these experiments and infected mice with a dose titration of parasites ranging from 0.1 
to 1.0 × 108 parasites per mouse (Fig. 3A). In general, parasite loads throughout the infection time course corre-
lated with the initial dose (Fig. 3A), and was separately quantiied in the liver (Fig. 3B) and spleen (Fig. 3C) using 
in vivo light-based imaging. We observed a linear increase in hepatic bioluminescence over the irst three weeks 
of infection (Fig. 3B), which extended to the fourth week in mice infected with lower parasite doses, before resolv-
ing. he increases in liver bioluminescence were found to be directly proportional to the number of parasites used 
to initially infect the animals (Fig. 3D). Monitoring of mice infected with 1 × 108 L. donovani parasites during the 
irst 24 hours of infection revealed parasites to rapidly localise to the liver within the irst hour, followed by a rapid 
decline in bioluminescence over the next two to eight hours (Fig. 3E). Of the initial signal in the liver one hour 
following infection, only a fraction (~3%) remained ater 24 hours suggesting BALB/c macrophages are highly 
competent at parasite clearance. his observation may also be a result of only a fraction of the parasites being 
Figure 2. Infections are dependent on the duration of stationary phase parasite culture. (A) Fresh cultures of 
luciferase-expressing transgenic L. donovani parasites were established at an initial seeding density of 1 × 106 
cells/mL and growth was quantiied over 12 days by counting live (motile) cells using a haemocytometer. Ater 
peaking at around days 3 to 7, motile parasite numbers declined. (B) Parasites were harvested at the speciied 
time and used to infect groups of ive mice intravenously. Infections were monitored during the initial 2–3 
weeks by in vivo imaging. hree representative animals from the group are shown and are arranged so that the 
infection dynamics can be followed in each individual animal throughout the course of the infection.
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Figure 3. he progression and severity of L. donovani infection of mice is dependent upon the initial inoculum 
size. (A) Groups of three mice were infected intravenously with diferent doses of day-seven stationary-phase 
L. donovani promastigotes and infections were monitored over 20 weeks by in vivo imaging. To quantify the 
parasite load, the bioluminescence (total lux, photon/sec) associated with the liver (B) and spleen (C) was 
measured. Mice were infected with 0.10 × 108 (white circles), 0.25 × 108 (blue circles), 0.50 × 108 (red circles) 
or 1.00 × 108 (green circles) parasites, respectively. Liver-associated bioluminescence increased linearly during 
the initial 1–3 weeks, analysed using linear regression in GraFit and plotted as dashed lines. he progression 
of infection of the liver during the initial three weeks was also analysed using linear regression and increases 
in bioluminescence were found to be directly proportional to the parasite dose for weeks 1 (black circles), 2 
(blue circles) and 3 (green circles), respectively (D). he parasites’ rapid localisation and clearance in the liver 
within irst 24 h of infection were determined in mice challenged with 1 × 108 parasites (n = 5) (E). Liver 
bioluminescence was normalised using measurements at 1 hour post infection as control for 100%. Data points 
represent means ± S.E.M. (n = 3 for B, C and D) or (n = 5 for E).
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capable of successful diferentiation from promastigotes to amastigotes to establish an infection in the mamma-
lian host. Following this dramatic reduction, there was a linear increase in liver bioluminescence over the next 
three weeks which eventually resolved, falling below the limits of detection by between weeks six and eight. he 
reduction in hepatic parasite load was followed by dissemination to the spleen ater week six, although signals in 
the spleen could be detected during the irst six weeks in animals infected with the higher parasite doses. By con-
trast to the liver, parasitisation of the spleen between individual animals within the same group was more variable 
(Fig. 3C), although those animals receiving more parasites in the initial inoculum generally resulted in spleens 
with higher parasite loads. Given that 1 × 108 parasites per mouse resulted in reproducibly robust infections of 
both liver and spleen, and was, in general, very well tolerated, this dose was used in all subsequent studies.
The administration route of vaccine formulation aプected disease progression┻ he protective 
outcome of a protein-in-adjuvant formulation can sometimes be dependent on its route of administration and 
some adjuvants may cause general immunostimulatory efects that could afect the infection parameters of a disease 
model. To determine a vaccine formulation that would be compatible with our infection model, groups of mice 
were vaccinated with a control protein expressed using a mammalian expression system that we have shown is 
suitable for expressing extracellular parasite proteins in a biochemically active form44. We selected alum as a mild, 
human-compatible adjuvant and quantiied the initial progression of the infection in the liver when animals were 
vaccinated by one of three diferent routes: intraperitoneal, intramuscular or subcutaneous (Fig. 4). To reduce any 
general immunostimulatory efect of vaccine administration, mice were rested for four weeks ater the inal immu-
nisation prior to an infection challenge. Mice were immunised with a control protein rat Cd200_Cd444 enabling us 
to quantify the elicited antibody response and compare diferent immunisation regimens. While we have repeatedly 
observed that antigen administration in the peritoneal cavity can elicit higher antibody titres compared to the sub-
cutaneous and intramuscular routes (Fig. S3), surprisingly, control animals vaccinated through this route elicited 
partial protection against subsequent L. donovani liver parasitisation (Fig. 4A). Although antibody titres were lower 
with intramuscular and subcutaneous administration routes (Fig. S3), we observed no overt diference in L. dono-
vani infection dynamics when compared to unimmunised mice, suggesting these are more suitable administration 
routes to establish any protective immunological efects elicited by a vaccine (Fig. 4A). To investigate this further, we 
established that this was likely to be a general immunostimulatory efect of the adjuvant, since mice treated intra-
peritoneally with alum alone also showed partial protection. To determine if this also afected the subsequent pro-
gression of the infection to the spleen, control mice immunised either through the subcutaneous or intraperitoneal 
routes were followed for 14 weeks. We again observed that mice immunised in the peritoneal cavity, ater an initially 
higher parasitisation of the liver peaking at the second week, resolved the infection much more rapidly compared to 
unimmunised mice or those immunised subcutaneously (Fig. 4B). Intraperitoneal vaccination promoted parasite 
localisation to the spleen during the early stages of infections with higher splenic parasite loads consistently meas-
ured in the irst eight weeks, and this resolved faster ater week eight compared to unimmunised naïve and subcuta-
neously vaccinated mice (Fig. 4C). Because we observed little diference in infection progression between naïve mice 
and animals immunized subcutaneously, all vaccine formulations were subsequently administered subcutaneously.
Mice that resolved initial infection are resistant to reinfection. The 1 × 108 dose of parasites 
required to achieve repeatable experimental infections for comparative vaccine screening led to a concern that 
immunity could be overwhelmed and thereby mask any vaccine-elicited protective efects in our model. It is 
known that mice which have resolved an initial VL infection can generate protective immune responses making 
them resistant to subsequent infections45. To demonstrate that our infection model could be used to identify 
protective efects, we attempted to induce immunity by infecting mice with a dose of live parasites that could be 
cleared in a few weeks. Consistent with earlier experiments (Fig. 3A), mice infected with a dose of 107 parasites 
had reduced parasite loads in both their livers and spleens which gradually resolved so that in some animals it fell 
below the limit of detection by week 12 (Fig. S4). To determine if immunity was elicited, these mice were subse-
quently infected with 108 parasites which resulted in robust infections in non-immune control mice. We observed 
that those mice which had previously been exposed to the parasite were protected from subsequent L. donovani 
challenge compared to controls (Fig. 5). his protection included an inability to colonise the liver (Fig. 5B) and 
spleen (Fig. 5C). Together these data demonstrate that immunity to a challenge of 108 parasites in the infection 
model could be elicited by prior exposure to a lower dose of parasites.
Discussion
With the aim of establishing a reproducible and quantitative experimental infection model of VL for sys-
tematic vaccine testing, we have selected a transgenic strain of L. donovani constitutively expressing an 
mCherry-luciferase fusion protein and characterised the infection parameters in mice. his model allowed us to 
visually and quantitatively monitor parasite loads of infected visceral organs in individual mice by in vivo imaging 
and thereby establish important parameters such as the dose of parasite and route of infection.
One major advantage of this model which we believe will make it particularly suitable for systematic vaccine 
screening is that infections can be longitudinally monitored in individual mice. his helps to account for the hetero-
geneity observed in individual infections, and the method considerably reduces the numbers of animals that would 
be otherwise required if parasite loads were quantiied using terminal procedures such as classical tissue impression 
smears or limiting dilution methods. Indeed, we have found in vivo imaging with the transgenic parasites to be 
more sensitive, less subjective and time-consuming than these more established methods of quantifying infections. 
here are additional challenges, however, that would further improve the model such as more sophisticated higher 
resolution three-dimensional imaging that would more precisely localise the parasites within infected tissues.
Previous reports of experimentally infecting mice with visceralising Leishmania species have exclusively used 
intravenous delivery, without other routes being explicitly described46–48. We have investigated and demonstrated 
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how the parasites persisted at sites of injection with non-intravenous routes before being resolved. A possible 
explanation for diferences in pathology could be the development of protective versus suppressive adaptive 
immune responses induced by diferent inoculation routes and parasite doses as suggested previously23. Other 
possible reasons could be the availability of speciic host immune components required for interaction with 
parasite surface molecules or to facilitate subversion mechanisms for macrophage infection establishment49. 
Promastigote metacyclogenesis is an important virulence determinant for Leishmania spp. infections50,51, since 
metacyclic parasites are more resistant to serum complement lysis52–54. Axenic cultured parasites diferentiate 
to metacyclic promastigotes during stationary phase with nutrient depletion being reported as promoting fac-
tors55,56. Our study indicated only a subfraction of parasites (~3%) persisted in the livers of infected mice 24 hours 
following an infection challenge. Interestingly, Ficoll gradient centrifugation43 can be used to enrich for metacy-
clic promastigotes, and in our hands, typically yield 1–3% recovery. It is entirely possible that the persistent ~3% 
of bioluminescence signal in the liver correspond to the parasites that have diferentiated into metacyclogenic 
forms and able to resist responses mounted by the host immune system. We were, however, unable to establish 
a robust measurable murine infection using the small number (106) of Ficoll-gradient enriched cells, suggesting 
other factors such as presence of dead or moribund parasites in the innoculum may also be required57.
Figure 4. Route of adjuvant formulation delivery afects disease pathology in a murine model of L. donovani 
infection. (A) Groups of ive mice were immunised via intraperitoneal, subcutaneous or intramuscular routes 
of injection with a control protein expressed in a mammalian expression system adsorbed to 1% or 0.5% 
alum. Mice were challenged intravenously with 108 stationary-phase parasites, and an unimmunised mouse 
is present within each group (identiied by red arrows) as a control. Infections were monitored by IVIS ater 
1 week and those immunised in the peritoneal cavity showed a reduction in parasite burden compared to the 
naïve control mice and those immunised by subcutaneous and intramuscular routes. (B,C) Groups of ive 
mice were immunised via intraperitoneal or subcutaneous routes of injection with control protein adsorbed 
to 1% alum, challenged intravenously with 108 stationary-phase parasites and infections monitored compared 
to unimmunised naïve mice by in vivo imaging for 13 weeks. Bioluminescence (total lux, photon/sec) was 
quantiied around deined regions of interest overlying the liver (B) and spleen (C) for naïve (black circles), 
subcutaneously-immunised (white circles) or intraperitoneally-immunised (red circles) animals. Data points 
represent means ± S.E.M. (n = 5). Relative bioluminescence was calculated by arbitrary normalisation to signals 
at week 2 (liver) and week 12 (spleen) of subcutaneously-immunised animals.
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his infection model does not attempt to replicate the dose and route of natural parasite infection by sand 
ly bite but rather establish an experimental model that could be used to assess candidates in a comparative and 
quantitative manner. By inoculating a precisely quantiied dose of parasites directly into the circulation, we can 
reduce some variables such as diferences in the number of transmitted parasites during a sand ly blood meal. A 
similar approach has been very useful to reduce variability and increase the sensitivity to assess vaccine eicacy in 
controlled human malaria infections by delivering a precise number of cryopreserved P. falciparum sporozoites by 
needle rather than through mosquito bite58. Our inding that the parasite growth in the liver in the irst few weeks 
of infection was linear and correlated with the dose of parasites provides a sensitive system to assess even partial 
efects of vaccines. Importantly, we have established that immunity can be established in our murine infection 
model by demonstrating the resistance of mice to reinfection following successful resolution of a prior infection, 
in good agreement with previous studies45,59. It also gave us further conidence that the dose of 108 parasites which 
resulted in repeatable and robust infections does not overwhelm the capacity of the animals’ immune system to 
resist infections ater immunity was acquired.
In vaccine development, adjuvants are usually required to elicit appropriate and long-lasting protective 
immune responses, particularly with subunit proteins that oten lack intrinsic immunogenicity. he immunologi-
cal mechanisms of action of some adjuvants are not yet fully understood, but are likely to involve the stimulation of 
multiple components of the host immune system60. Although many adjuvants have been developed and optimised 
Figure 5. Mice that resolved an initial infection are resistant to reinfection with 108 parasites. (A) Two 
groups of ive mice were pre-exposed to live parasites by intravenously infecting them with a suboptimal 
dose of 107 parasites per mouse; ater 16 weeks, no parasites were detected by in vivo imaging. One group was 
then reinfected intravenously with 108 parasites (week 0), while the second group served as a control for any 
possible disease progression from the pre-exposure infection. A third group of naïve control mice was infected 
intravenously with 108 parasites as a positive control for virulence of the inoculum. By contrast to controls, mice 
that had been previously exposed to live parasites were immune to subsequent reinfection. hree representative 
animals from the group are shown and are arranged so that the infection dynamics can be followed in each 
individual animal throughout the course of the infection. (B,C) Bioluminesence (total lux, photon/sec) were 
quantiied around deined regions of interest corresponding to the liver (B) and spleen (C). Group 1 (red circles, 
n = 4), Group 2 (white circles, n = 5) or Group 3 (black circles, n = 9) animals. Data points represent means ± 
S.E.M. of measurements. Relative bioluminescence was calculated by arbitrary normalisation to signals at week 
2 (liver) and week 12 (spleen) of naive control-infected animals.
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to stimulate speciic immune responses, only a handful have been approved for use in humans. Since the most 
common human-compatible adjuvant used in vaccines are aluminium salts (alum) which are used in the majority 
of licensed human vaccines, its suitability for use against VL was investigated in our model. More importantly, 
soluble leishmania surface antigens adjuvanted with alum were previously shown to be protective in a murine VL 
infection model61. To minimise and account for general adjuvant-based stimulation of host immunity, we have 
incorporated a “resting” period into our immunisation schedule, where vaccinated animals were “rested” for four 
weeks following the inal boost before being infected. Alum was found to be a suitable adjuvant when adminis-
tered subcutaneously or intramuscularly but not intraperitoneally. Although intraperitoneal administration would 
not be considered for humans, these indings highlight important considerations when using alum or any other 
adjuvants in vaccinology studies against VL or other diseases. In summary, we have established a robust, sensitive, 
and reproducible murine experimental infection model of visceral leishmaniasis. We envisage that this model will 
provide an important platform to facilitate systematic testing of the many subunit vaccine candidates that have 
been identiied from the recent advances in genome sequencing and gene annotation. he eventual goal will be to 
use this model to identify a range of potential vaccine targets to help treat and prevent this deadly disease.
Methods
Ethics statement. All animal experiments were performed under UK Home Oice governmental regula-
tions and European directive 2010/63/EU. Research was approved by the Sanger Institute Animal Welfare and 
Ethical Review Board.
Generation of transgenic L. donovani expressing mCherry and Luciferase. Transgenic parasites 
were generated by transfection of the wild-type LV9 strain of L. donovani with an integrating construct leading to 
stable luciferase expression. Briely, the gene irely luciferase was cloned into the XmaI site (SmaI isoschizomer) 
of pIR1SAT, an integrating vector that was kindly provided to us by Dr. Stephen M. Beverley of Washington 
University, St. Louis62. he vector was digested with SwaI generating products of 2860 and 5630 bp, whose sizes 
were veriied on agarose gel electrophoresis. he reaction product with the two unseparated fragments were 
introduced by electroporation into promastigotes in logarithmic stage growth by electroporation as described63 
and selection on semi-solid medium with 100 µg/mL nourseothricin. Ater 2–4 weeks at 26 °C, drug-resistant 
clones were picked and ampliied in liquid growth medium with 100 ug/mL nourseothricin. Correct homologous 
integration of the insert was veriied by Southern blotting as previously described for the generation of luciferase 
expressing L. infantum35 or by PCR of genomic DNA.
L. donovani promastigote culture and animal infections. Parasites were cultured at 28 °C in LdPro 
medium64 supplemented with 100 µg/mL nourseothricin and 10 U/mL penicillin-streptomycin (Gibco). Parasites 
for infecting animals were prepared by subculturing cells at an initial seeding density of 1 × 106 cells/mL. 
Stationary phase promastigotes were harvested by centrifugation (2000 × g, 10 mins) and washed twice with PBS. 
Parasites were resuspended at appropriate densities in DMEM medium (Sigma) and used to infect BALB/c mice 
intravenously, intraperitoneally or subcutaneously at 200 µL/injection/animal. Infections were monitored by in 
vivo imaging at regular deined intervals. To maintain virulence, parasites were harvested from spleens of infected 
animals as previously described65, with minor modiications. Briely, organs were suspended in LdPro medium 
(5 mL/g) and homogenised using the gentleMACS Dissociator (Miltenyi Biotec) with M-tubes. Tissue extracts 
were treated with saponin (50 µg/mL) and clariied by two rounds of centrifugation (200 × g and 2000 × g) as 
previously described65. Final pellets were resuspended in LdPro medium and incubated at 28 °C to allow amastig-
otes to diferentiate into promastigotes. Aliquots of freshly diferentiated promastigotes were stored as stabilates 
at −80 °C using 10% (v/v) glycerol as a cryoprotectant. To minimise variability between infection challenges, 
promastigote preparations that had been maintained in culture for no longer than two weeks were routinely used.
Monitoring infection in vivo imaging. D-luciferin (K+ salt, BioVision, Inc.) was reconstituted to 30 mg/
mL in Dulbecco’s PBS without Ca2+ and Mg2+ (Hyclone), ilter-sterilised (0.22 µm) and stored in aliquots at 
−20 °C. hawed aliquots were administered to animals intraperitoneally at 300 mg/kg. Injected animals were 
allowed free movement for three minutes before being anaesthetized in an anaesthesia chamber attached to the 
In Vivo Imaging System (IVIS Spectrum, PerkinElmer) using 3% gaseous isolurane. Anaesthetised mice were 
moved to the imaging chamber and general anaesthesia was maintained using 3% gaseous isolurane adminis-
tered through built-in nose cones attached to a manifold until data acquisition was completed. Bioluminescence 
acquisitions were performed ten minutes ater luciferin injection using ixed parameters of exposure 3 min, bin-
ning medium 8.0 and f/stop 1.0, respectively. Data were analysed using the Living Image sotware, with biolu-
minescence signal converted to radiance (photons/sec/cm2/sr) using a ixed normalised scale on IVIS images of 
animals. Bioluminescence quantiied around deined regions of interest overlying to the location of the liver or 
spleen was expressed as total lux (photons/sec) and analysed using GraFit. IVIS images were normalised to a 
ixed scale with radiance limits set at 5 × 103 (minimum) and 1 × 105 (maximum).
Immunisations and determination of antibody titres. Mice used in the study were produced by the 
Research Support Facility at the Wellcome Sanger Institute. Rat Cd200-Cd4 fusion protein was expressed in a 
mammalian expression system (HEK293 cells) and puriied as previously described44 and used as a control pro-
tein for immunisations to quantify immune responses. Control proteins were mixed with 2% alum (Alhydrogel, 
InvivoGen) at a 1:1 (v/v) ratio and incubated on a roller mixer for 1 h at 22 °C. Groups of BALB/c mice (6–7 
weeks old) were immunised by injecting the protein-alum mix either intraperitoneally (200 µL into peritoneal 
cavity), subcutaneously (2 × 100 µL into lank regions) or intramuscularly (2 × 50 µL into muscles in the hind 
legs). Booster shots were similarly prepared and administered on days 14 and 28 following the initial immunisa-
tion. Control proteins were administered to mice at 100 µg and 20 µg per animal in the initial immunisation and 
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subsequent boosters, respectively. Sera were harvested from tail bleeds of immunised mice 8 days ater the inal 
immunisation, with antibody titres determined using ELISA as previously described66. Briely, a ixed concentra-
tion of the biotinylated control protein was immobilised on 96-well streptavidin plates (hermo Scientiic) and 
incubated with serial dilutions of the corresponding sera prepared in HBS/0.1% (v/v) Tween 20 (HBST), contain-
ing 2% (w/v) BSA. his was followed by three washes with HBST before incubation with a secondary alkaline 
phosphatase (AP) conjugated anti-mouse IgG (Sigma) for 1 h. Following three further washes with HBST, AP 
substrate (100 µL, 1 mg/mL in ELISA bufer, Sigma) was added and AP activity was quantiied at 405 nm using 
a plate reader (Tecan). Results were analysed using four parameter non-linear regression in GraFit. Mice were 
infected with L. donovani intravenously 28 days ater the inal immunisation.
Data availability
All data are available in the article text and igures or supplementary iles, and available from the corresponding 
author upon reasonable request.
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